International Post Stroke Epilepsy Research Consortium (IPSERC): A consortium to accelerate discoveries in preventing epileptogenesis after stroke

for International Post Stroke Epilepsy Research Consortium (IPSERC)

doi:10.1016/j.yebeh.2021.108502

International Post Stroke Epilepsy Research Consortium (IPSERC): A consortium to accelerate discoveries in preventing epileptogenesis after stroke

for International Post Stroke Epilepsy Research Consortium (IPSERC)

Research output: Contribution to journal › Editorial

10 Scopus citations

Original language	English
Article number	108502
Journal	Epilepsy and Behavior
Volume	127
DOIs	https://doi.org/10.1016/j.yebeh.2021.108502
State	Published - Feb 2022

Access to Document

10.1016/j.yebeh.2021.108502

Cite this

@article{679cf4680a804ecab326a9e1e3d7017a,

title = "International Post Stroke Epilepsy Research Consortium (IPSERC): A consortium to accelerate discoveries in preventing epileptogenesis after stroke",

author = "{for International Post Stroke Epilepsy Research Consortium (IPSERC)} and Mishra, {Nishant K.} and Jerome Engel and Liebeskind, {David S.} and Sharma, {Vijay K.} and Hirsch, {Lawrence J.} and Kasner, {Scott E.} and French, {Jacqueline A.} and Orrin Devinsky and Alon Friedman and Jesse Dawson and Quinn, {Terence J.} and Magdy Selim and {de Havenon}, Adam and Yasuda, {Clarissa L.} and Fernando Cendes and Felix Benninger and Zaveri, {Hitten P.} and Burneo, {Jorge G.} and Padma Srivastava and {Bhushan Singh}, Mamta and Rohit Bhatia and Vishnu, {V. Y.} and Carla Bentes and Jose Ferro and Shennan Weiss and Adithya Sivaraju and Kim, {Jennifer A.} and Marian Galovic and Gilmore, {Emily J.} and Asla Pitk{\"a}nen and Kathryn Davis and Sansing, {Lauren H.} and Sheth, {Kevin N.} and Paz, {Jeanne T.} and Anuradha Singh and Sunil Sheth and Worrall, {Bradford B.} and Grotta, {James C.} and Casillas-Espinos, {Pablo M.} and Zhibin Chen and Nicolo, {John Paul} and Bernard Yan and Patrick Kwan",

note = "Funding Information: VY Vishnu has research grants from the DST, DBT, and ICMR. He is currently conducting an investigator initiated RCT on primary prevention of post stroke seizures funded by Department of Science and Technology (DST), Government of India. Funding Information: Hitten P Zaveri has research grants from NIH and the Swebilius Foundation. He is a co-founder of Alva Health and an inventor on patents for monitoring the brain, focal brain cooling and detection of stroke. Funding Information: Jerome Engel , Jr. is funded by NIH, and has received consultation fees from Cerebellum and Eisai. Funding Information: Asla Pitk{\"a}nen receives grants from the NIH, European Union, and Medical Research Council of the Academy of Finland. She has consulting agreements with Angelini Pharma and NeuroTrauma sciences. Funding Information: Patrick Kwan is supported by a Medical Research Future Fund Practitioner Fellowship (MRF1136427). His institution has received research grants from Biscayne Pharmaceuticals, Eisai, GW Pharmaceuticals, LivaNova, Novartis, UCB Pharma, and Zynerba outside the submitted work; he has received speaker fees from Eisai, LivaNova, and UCB Pharma outside the submitted work. Funding Information: Orrin Devinsky receives grant support from NINDS, NIMH, MURI, CDC and NSF. He has equity and/or compensation from the following companies: Privateer Holdings, Tilray, Receptor Life Sciences, Qstate Biosciences, Tevard, Empatica, Engage, Egg Rock/Papa & Barkley, Rettco, SilverSpike, and California Cannabis Enterprises (CCE). He has received consulting fees from GW Pharma, Cavion, Zogenix, Ultragenyx, BridgeBio, and Marinus. He holds patents for the use of cannabidiol in treating neurological disorders, but these are owned by GW Pharmaceuticals, and he has waived any financial stake in these patents. He holds other patents in molecular biology. Funding Information: Kathryn A Davis receives grant support from NIH and investigator-initiated research support from Eisai pharmaceuticals. She has served on advisory boards for Eisai Pharmaceuticals, Eton Pharmaceuticals, GW Pharmaceuticals and SK Life Sciences. She serves as a consultant for Pfizer. Funding Information: Bradford B. Worrall receives grant support from NINDS, NCATS, NIA. He is Deputy Editor for Editorial Education for the journal Neurology. He reports no conflicts of interest for the topic of this paper. Funding Information: Pablo Casillas-Espinosa reports no conflict of interest for this topic, but he acknowledges funding for the following: National Health and Medical Research Council (NHMRC, Australia), The Brain Foundation or Australia, Department of Defense USA, CSIRO/Data 61 and has received funding for investigator-initiated projects from Eisai, Supernus, Praxis and Kaoskey. Funding Information: Kevin N. Sheth has research grants from the NIH and American Heart Association. He has received consulting fees or equity from Rhaeos, Certus Critical Care, Ceribell, and is the DSMB chair for a Zoll funded stroke study, as well as a DSMB member for Sense Diagnostics. Research grants have been provided to Yale in support of his work from Biogen, Novartis, Bard, and Hyperfine. He is a co-founder of Alva Health. Funding Information: Zhibin Chen reports no conflict of interest for this topic, but reports the following: he is supported by an Early Career Fellowship from the National Health and Medical Research Council (NHMRC) of Australia (GNT 1156444), and he/his institution has received consultancy fees and/or research grants from Arvelle Therapeutics and UCB Pharma. ",

year = "2022",

month = feb,

doi = "10.1016/j.yebeh.2021.108502",

language = "English",

volume = "127",

journal = "Epilepsy and Behavior",

issn = "1525-5050",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - International Post Stroke Epilepsy Research Consortium (IPSERC)

T2 - A consortium to accelerate discoveries in preventing epileptogenesis after stroke

AU - for International Post Stroke Epilepsy Research Consortium (IPSERC)

AU - Mishra, Nishant K.

AU - Engel, Jerome

AU - Liebeskind, David S.

AU - Sharma, Vijay K.

AU - Hirsch, Lawrence J.

AU - Kasner, Scott E.

AU - French, Jacqueline A.

AU - Devinsky, Orrin

AU - Friedman, Alon

AU - Dawson, Jesse

AU - Quinn, Terence J.

AU - Selim, Magdy

AU - de Havenon, Adam

AU - Yasuda, Clarissa L.

AU - Cendes, Fernando

AU - Benninger, Felix

AU - Zaveri, Hitten P.

AU - Burneo, Jorge G.

AU - Srivastava, Padma

AU - Bhushan Singh, Mamta

AU - Bhatia, Rohit

AU - Vishnu, V. Y.

AU - Bentes, Carla

AU - Ferro, Jose

AU - Weiss, Shennan

AU - Sivaraju, Adithya

AU - Kim, Jennifer A.

AU - Galovic, Marian

AU - Gilmore, Emily J.

AU - Pitkänen, Asla

AU - Davis, Kathryn

AU - Sansing, Lauren H.

AU - Sheth, Kevin N.

AU - Paz, Jeanne T.

AU - Singh, Anuradha

AU - Sheth, Sunil

AU - Worrall, Bradford B.

AU - Grotta, James C.

AU - Casillas-Espinos, Pablo M.

AU - Chen, Zhibin

AU - Nicolo, John Paul

AU - Yan, Bernard

AU - Kwan, Patrick

N1 - Funding Information: VY Vishnu has research grants from the DST, DBT, and ICMR. He is currently conducting an investigator initiated RCT on primary prevention of post stroke seizures funded by Department of Science and Technology (DST), Government of India. Funding Information: Hitten P Zaveri has research grants from NIH and the Swebilius Foundation. He is a co-founder of Alva Health and an inventor on patents for monitoring the brain, focal brain cooling and detection of stroke. Funding Information: Jerome Engel , Jr. is funded by NIH, and has received consultation fees from Cerebellum and Eisai. Funding Information: Asla Pitkänen receives grants from the NIH, European Union, and Medical Research Council of the Academy of Finland. She has consulting agreements with Angelini Pharma and NeuroTrauma sciences. Funding Information: Patrick Kwan is supported by a Medical Research Future Fund Practitioner Fellowship (MRF1136427). His institution has received research grants from Biscayne Pharmaceuticals, Eisai, GW Pharmaceuticals, LivaNova, Novartis, UCB Pharma, and Zynerba outside the submitted work; he has received speaker fees from Eisai, LivaNova, and UCB Pharma outside the submitted work. Funding Information: Orrin Devinsky receives grant support from NINDS, NIMH, MURI, CDC and NSF. He has equity and/or compensation from the following companies: Privateer Holdings, Tilray, Receptor Life Sciences, Qstate Biosciences, Tevard, Empatica, Engage, Egg Rock/Papa & Barkley, Rettco, SilverSpike, and California Cannabis Enterprises (CCE). He has received consulting fees from GW Pharma, Cavion, Zogenix, Ultragenyx, BridgeBio, and Marinus. He holds patents for the use of cannabidiol in treating neurological disorders, but these are owned by GW Pharmaceuticals, and he has waived any financial stake in these patents. He holds other patents in molecular biology. Funding Information: Kathryn A Davis receives grant support from NIH and investigator-initiated research support from Eisai pharmaceuticals. She has served on advisory boards for Eisai Pharmaceuticals, Eton Pharmaceuticals, GW Pharmaceuticals and SK Life Sciences. She serves as a consultant for Pfizer. Funding Information: Bradford B. Worrall receives grant support from NINDS, NCATS, NIA. He is Deputy Editor for Editorial Education for the journal Neurology. He reports no conflicts of interest for the topic of this paper. Funding Information: Pablo Casillas-Espinosa reports no conflict of interest for this topic, but he acknowledges funding for the following: National Health and Medical Research Council (NHMRC, Australia), The Brain Foundation or Australia, Department of Defense USA, CSIRO/Data 61 and has received funding for investigator-initiated projects from Eisai, Supernus, Praxis and Kaoskey. Funding Information: Kevin N. Sheth has research grants from the NIH and American Heart Association. He has received consulting fees or equity from Rhaeos, Certus Critical Care, Ceribell, and is the DSMB chair for a Zoll funded stroke study, as well as a DSMB member for Sense Diagnostics. Research grants have been provided to Yale in support of his work from Biogen, Novartis, Bard, and Hyperfine. He is a co-founder of Alva Health. Funding Information: Zhibin Chen reports no conflict of interest for this topic, but reports the following: he is supported by an Early Career Fellowship from the National Health and Medical Research Council (NHMRC) of Australia (GNT 1156444), and he/his institution has received consultancy fees and/or research grants from Arvelle Therapeutics and UCB Pharma.

PY - 2022/2

Y1 - 2022/2

UR - http://www.scopus.com/inward/record.url?scp=85121986134&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2021.108502

DO - 10.1016/j.yebeh.2021.108502

M3 - Editorial

C2 - 34968775

AN - SCOPUS:85121986134

SN - 1525-5050

VL - 127

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

M1 - 108502

ER -